BioSpace News Archive

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presented today final data from the Phase II trial SATEEN on vafidemstat’s ability to reduce the inflammatory response in multiple sclerosis (MS) patients.

TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced the appointment of Carol Lam to its Board of Directors.

I-Mab (the “Company”) (NASDAQ: IMAB), today announced that it has completed the patient enrollment of the phase 3 clinical trial of human CD38 antibody felzartamab (also known as TJ202) in combination with lenalidomide as a second-line therapy in patients with multiple myeloma (MM).

GlobalLogic Inc. , a Hitachi Group Company and leader in Digital Engineering, today announced that it has been selected by Inspira Technologies to develop an algorithm-enhanced digital platform powering the ART device

Horizon Therapeutics plc (Nasdaq: HZNP) today announced results from a new analysis of the UPLIZNA pivotal Phase 2/3 N-MOmentum trial indicating a correlation between the depth of B-cell depletion and improved NMOSD patient outcomes.

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced the time of its third quarter 2021 earnings release and conference call.

GBS Inc., a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, announced it has filed a Pre-Submission package with the United States Food and Drug Administration.

Cohealo, a platform for health systems to track and share medical equipment, today announced that Tom Cady will join Cohealo’s leadership team as chief operating officer.

Dyne Therapeutics, Inc hosts its first Research and Development Day today focused on the Company’s co-lead development programs for rare muscle diseases, Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).

Selecta Biosciences, Inc. (NASDAQ: SELB), today announced it will be presenting preclinical data in four posters highlighting its ImmTOR nanoparticle platform and its potential to safely enable repeat vector dosing in gene therapy patients at the 28th Annual Congress of the European Society of Gene & Cell Therapy